Search

Search Constraints

You searched for: Author/Creator Gogas, Helen

Search Results

61. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (November 2019)

62. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Issue 2 (1st September 2022)

63. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma. Issue 3 (30th March 2021)

64. The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. (October 2021)

65. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (September 2017)

66. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Issue 2 (2nd November 2020)

67. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Issue 2 (2nd November 2020)

68. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Issue 2 (2nd November 2020)

69. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Issue 2 (2nd November 2020)